Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
GenSci164 is a biological therapeutic candidate developed by Changchun GeneScience Pharmaceutical (GenSci) for the treatment of hypoparathyroidism. As a biological product designed for subcutaneous injection, it likely functions as an agonist of the parathyroid hormone receptor, aiming to restore calcium and phosphate homeostasis in patients with deficient endogenous parathyroid hormone levels. The drug is currently undergoing early-stage clinical evaluation, including a Phase 1 randomized, double-blind, placebo-controlled dose-escalation study in healthy Chinese adults to assess its safety, tolerability, pharmacokinetics, and pharmacodynamics.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on GenSci164.